Clastogenicity of selective serotonin-reuptake inhibitors

Bozkurt G., Abay E., Ates I., Karabogaz G., Ture M., Savran F., ...More

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, vol.558, pp.137-144, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 558
  • Publication Date: 2004
  • Doi Number: 10.1016/j.mrgentox.2003.11.005
  • Journal Name: MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.137-144
  • Keywords: chromosome aberration, selective serotonin-reuptake inhibitors, sertraline, indicator for detecting clastogenicity, sister chromatid exchanges, cells with high-frequency sister chromatid exchanges (HFC), SISTER-CHROMATID EXCHANGE, OCCUPATIONAL EXPOSURE, DOPAMINE TRANSPORTER, BLOOD-LYMPHOCYTES, DNA-DAMAGE, CHROMOSOME, FREQUENCY, CELLS, RECOMBINATION, MUTAGENICITY
  • Istanbul University Affiliated: Yes

Abstract

Objective: Selective serotonin-reuptake inhibitors (SSRIs) are used in the treatment of various forms of psychiatric disorders. Preclinical studies in laboratory animals have indicated that SSRIs were not genotoxic, but clear results from in vitro testing of SSRIs in a human cell system are currently scarce. The purpose of this study was to investigate whether SSRIs might be genotoxic. Sertraline was chosen as model SSRI, since it appears to be at least as well-tolerated as other SSRIs and may even have a more favourable side-effect profile. Unlike fluoxetine, fluvoxamine and paroxetine, sertraline has low potential for pharmacokinetic drug interactions. So, sertraline would be considered first in the treatment of psychiatric disorders requiring SSRI therapy in the future. We therefore examined peripheral lymphocytes from sertraline-treated patients for both sister chromatid exchanges (SCEs), cells with a high frequency of SCEs (HFC) and chromosome aberrations (CA) to evaluate the elastogenicity of SSRIs.